Jihye Lee

Jihye Lee

Auto-generated profile, based on publicly available information

Jihye Lee

Basgenbio, Inc

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2023 in Research Square
Verified
Preprint
Open access
PDF file
JKJung Oh Kim
Jung Oh Kim
SLSun Yeop Lee
Sun Yeop Lee
EKEun Gyo Kim
Eun Gyo Kim
ELEunbyeol Lee
Eunbyeol Lee
JLJihye Lee
Jihye Lee
YSYu Jeong Shim
Yu Jeong Shim
Multiomics-based efforts to identify therapeutic targets for IBD have been limited to European populations. Prior reports on heterogeneity between East Asians and Europeans in clinical manifestations of IBD and genetic architectures of IBD-related variants warrant a separate investigation in East Asians. Using the East Asian genome and proteome data, we applied two multiomics-based causal inference methods, proteome-wide Mendelian randomization and causal proteome-wide association study. For IBD, Crohn’s disease (CD), and ulcerative colitis (UC), we found 30 potential drug targets with proteomic evidence. IL18R1, IL1RL1, KIR3DL1, and MEP1B had consistent associations with across IBD, CD, and UC. Fifteen targets were CD-specific, while eight were UC-specific. Among the candidate targets, thirteen and eight had supportive MR evidence in the plasma transcriptome data and the multi-tissue transcriptome data of European ancestry, respectively. IL18R1, IL6R, IL16, TNFRSF14 or their direct interactors were currently targeted by drugs being developed to treat IBD. IL1RL1 and PDGFRB had existing drugs that may be repurposed for IBD. Crucially, we identified six previously unreported target genes, opening new avenues for therapeutic interventions in IBD that warrant immediate validation in upcoming experiments and clinical trials.